Development of novel imaging agents for the prospective quantification of joint damage to reduce animal numbers in osteoarthritis research

开发新型成像剂,用于前瞻性量化关节损伤,以减少骨关节炎研究中的动物数量

基本信息

  • 批准号:
    NC/M000141/1
  • 负责人:
  • 金额:
    $ 43.07万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2015
  • 资助国家:
    英国
  • 起止时间:
    2015 至 无数据
  • 项目状态:
    已结题

项目摘要

Osteoarthritis (OA) is the most common form of arthritis and a leading cause of pain and disability, where there is progressive loss of joint function due to continual erosion and remodelling of the tissues of the joint. There are currently no modifying treatments for disease and patients rely on simple pain killers and ultimately joint replacement surgery. Investigating the pathways that cause disease has been very challenging as the human condition is very variable in its course, it is difficult to obtain tissues from patients (except at joint replacement surgery) and we currently have no ways of detecting early disease. Animal models of OA have significant utility because disease can be studied at all stages of the condition, tissues are readily available, and the onset of disease is known. In the past 10 years a number of advances have arisen from the use of mouse models of OA induced by surgical joint destabilisation. Combining these models with mice that have genetic modification has revealed several key pathways/molecules important for the OA process. Many academic and pharmaceutical companies use these models for such investigations. Progress in developing novel treatments for OA is very likely to arise from pre-clinical models.Evaluation of joint damage both in the clinic and in animal models of OA is hampered by the inability to image cartilage accurately and non-invasively. X-ray radiographs measure cartilage loss by a reduction in the joint space, thus are only able to pick up relatively advanced disease. In animal models, joint damage is typically assessed by histology after sacrificing the animals at regular intervals throughout studies (usually 4-12 weeks). The latter increases the number of animals used in each study by the number of time points required. A non-invasive imaging method that would be able to visualise the degradation of the articular cartilage over time would greatly reduce the numbers of animals being used in arthritis research. Such a system, being quantitative, might also increase the reliability of measurements and thus also reduce numbers. We have already demonstrated that it is possible to tag cartilage specific molecules to visualise the cartilage specifically. In this project, we will develop a novel imaging agent that can be combined with microCT scanning to create a sensitive, quantitative cartilage assessment tool in OA. This will initially dramatically reduce the number of animals used per OA study and is potentially translatable into a clinical imaging agent for early OA in humans.
骨关节炎(OA)是关节炎的最常见形式,并且是疼痛和残疾的主要原因,其中由于关节组织的持续侵蚀和重塑而存在关节功能的进行性丧失。目前没有针对疾病的改良治疗方法,患者依赖于简单的止痛药,最终进行关节置换手术。调查导致疾病的途径一直非常具有挑战性,因为人类的状况在其过程中非常多变,很难从患者身上获得组织(关节置换手术除外),我们目前没有办法检测早期疾病。OA的动物模型具有重要的实用性,因为疾病可以在病症的所有阶段进行研究,组织容易获得,并且疾病的发作是已知的。在过去的10年中,由于使用了由手术关节失稳诱导的OA小鼠模型,取得了许多进展。将这些模型与具有遗传修饰的小鼠相结合,揭示了对OA过程重要的几个关键途径/分子。许多学术和制药公司使用这些模型进行此类调查。在开发新的治疗OA的进展是很可能出现在临床前model.Evaluation关节损伤的临床和动物模型的OA是由于无法成像软骨准确和非侵入性。X光片通过关节间隙的减少来测量软骨损失,因此只能发现相对晚期的疾病。在动物模型中,关节损伤通常在整个研究中定期处死动物(通常为4-12周)后通过组织学评估。后者根据所需的时间点数量增加了每项研究中使用的动物数量。一种非侵入性的成像方法,能够可视化关节软骨随着时间的推移而退化,这将大大减少关节炎研究中使用的动物数量。这样一个定量的系统也可能增加测量的可靠性,从而减少数量。我们已经证明了标记软骨特异性分子以特异性地可视化软骨是可能的。在这个项目中,我们将开发一种新的成像剂,可以与microCT扫描相结合,以创建一个敏感的,定量的软骨评估工具在OA。这最初将大大减少每个OA研究使用的动物数量,并可能转化为人类早期OA的临床成像剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tonia Vincent其他文献

199 - Are there systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis? A biological substudy from the PROMOTE randomised controlled clinical trial
199 - 对于患有膝关节疼痛性骨关节炎的患者,是否存在能反映对甲氨蝶呤治疗有反应的系统性生物标志物?来自PROMOTE随机对照临床试验的一项生物学子研究
  • DOI:
    10.1016/j.joca.2025.02.203
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    9.000
  • 作者:
    Jiahao Liang;Artemis Papadaki;Jennifer Alderson;Tonia Vincent;Philip G. Conaghan;Sarah R. Kingsbury;Fiona E. Watt
  • 通讯作者:
    Fiona E. Watt
006 - REMODELLING OF VASCULATURE AND NERVES IN MURINE JOINTS FOLLOWING SURGICAL JOINT DESTABILISATION
  • DOI:
    10.1016/j.joca.2024.02.017
  • 发表时间:
    2024-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Vicky Batchelor;Jadwiga Miotla-Zarebska;Tonia Vincent
  • 通讯作者:
    Tonia Vincent
646 - Unravelling the phenotype of surviving chondrocytes after cartilage injury
  • DOI:
    10.1016/j.joca.2024.02.661
  • 发表时间:
    2024-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Linyi Zhu;Lada Koneva;Stephen Sansom;Jana Riegger;Tonia Vincent
  • 通讯作者:
    Tonia Vincent
Vaccination against nerve growth factor is an effective pain treatment in murine osteoarthritis
  • DOI:
    10.7861/clinmedicine.19-2-s111
  • 发表时间:
    2019-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Isabell von Loga;Aadil El-Turabi;Jadwiga Zarebska;Martin Bachmann;Tonia Vincent
  • 通讯作者:
    Tonia Vincent
Arthritis : Is This the Road to Clinical Development and Acceptance ? Defining the Mechanism of Action of Herbal Therapies in Rheumatoid
关节炎:这是临床开发和接受的道路吗?
  • DOI:
    10.1142/9781848163218_0003
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sonya Abraham;Andrew Barr;Michael Doherty;Andrew Keat;Bina Menon;Elena Nikiphorou;Leena Patel;P. Taylor;Tonia Vincent;Fiona Watt
  • 通讯作者:
    Fiona Watt

Tonia Vincent的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tonia Vincent', 18)}}的其他基金

Do systemic metabolites drive the chondroprotective effects of the IL18-/- gut microbiome in osteoarthritis?
全身代谢物是否驱动 IL18-/- 肠道微生物组在骨关节炎中的软骨保护作用?
  • 批准号:
    MR/W003597/1
  • 财政年份:
    2021
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Research Grant
Retinoic acid metabolism blocking agents (RAMBAs) to treat hand osteoarthritis
视黄酸代谢阻断剂(RAMBA)治疗手部骨关节炎
  • 批准号:
    MR/S035664/1
  • 财政年份:
    2020
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Research Grant

相似国自然基金

Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
  • 批准号:
    82070530
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
  • 批准号:
    32002421
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
  • 批准号:
    31902347
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bioorthogonal probe development for highly parallel in vivo imaging
用于高度并行体内成像的生物正交探针开发
  • 批准号:
    10596786
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Customizable Artificial Intelligence for the Biomedical Masses: Development of a User-Friendly Automated Machine Learning Platform for Biology Image Analysis.
面向生物医学大众的可定制人工智能:开发用于生物图像分析的用户友好的自动化机器学习平台。
  • 批准号:
    10699828
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
  • 批准号:
    10652788
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
  • 批准号:
    10760236
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Continuous development of nTracer2 and its deployment at NIH image repositories
nTracer2 的持续开发及其在 NIH 图像存储库中的部署
  • 批准号:
    10726178
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Development of multi-color 3D super-localization LiveFISH and LiveFISH PAINT to investigate the chromatin dynamics at any genomic scale
开发多色 3D 超定位 LiveFISH 和 LiveFISH PAINT,以研究任何基因组规模的染色质动态
  • 批准号:
    10725002
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Development of the multisensory computations underlying flavor processing
风味加工基础的多感官计算的发展
  • 批准号:
    10584065
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Catch and Release Radiolabeled Peptides: a new technology for radiotracer development
捕获并释放放射性标记肽:放射性示踪剂开发的新技术
  • 批准号:
    10593475
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Investigating the relationship between Sympathetic Nervous System Development and Neuroblastoma
研究交感神经系统发育与神经母细胞瘤之间的关系
  • 批准号:
    10658015
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
Elucidating signaling networks in Anterior Segment development, repair and diseases
阐明眼前节发育、修复和疾病中的信号网络
  • 批准号:
    10718122
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了